Moderna (MRNA) 3Q Earnings Miss
b'Moderna (MRNA) reported 3Q earnings with a miss on both EPS and revenue versus what was expected. Hartaj Singh of Oppenheimer compares Pfizer (PFE) to Moderna. Oppenheimer has a neutral rating on Moderna. He thinks Moderna is a good longer term play.'